Welcome to the e-CCO Library!

P464: Assessing medication adherence in patients with inflammatory bowel disease: what do we choose, self-adherence scales or pharmacy rates?
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. L. De Castro*1, L. Sanromán1, A. Martín2, N. Martínez2, M. Figueira1, V. Hernández1, J. R. Pineda1, J. Martínez-Cadilla1, S. Pereira1, V. Del Campo3, J.-I. Rodríguez-Prada1

Created: Friday, 22 February 2019, 9:49 AM
P464: Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panaccione, R.(1)*;Danese, S.(2);Wolf, D.C.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Afzali, A.(5);Abreu, M.T.(6);
Created: Friday, 14 July 2023, 11:05 AM
P464: Rac1/pSTAT3 expression in T lymphocytes: A potential pharmacodynamic marker for thiopurines in the treatment of Inflammatory Bowel Disease patients?
Year: 2022
Source: ECCO'22
Authors: DebenMSc, D.(1);Creemers, R.(2,3);Van Adrichem, A.(4);Drent, R.(5);Merry, A.(6);Leers, M.(5);Van Bodegraven, A.(2,7);Wong, D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P464: Recurrence of ulcerative colitis during pregnancy in patients who became pregnant during remission
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ito A.*1, Murasugi S.2, Kashiwagi H.2, Hara T.2, Omori T.1, Yonezawa M.1, Iizuka B.1, Tokushige K.2

Created: Wednesday, 20 February 2019, 10:36 AM
P464: Steroid dependency in patients with Ulcerative Colitis treated with advanced therapies in a German real-world-setting
Year: 2021
Source: ECCO'21 Virtual
Authors: Bokemeyer, B.(1);Picker, N.(2);Wilke, T.(3);Rosin, L.(4);Patel, H.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P464: Study of the usual aetiologies of methotrexate and azathioprine discontinuation in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Skamnelos*1, K. Katsanos1, D. Christodoulou1

Created: Friday, 22 February 2019, 9:41 AM
P464: Switching from the originator infliximab to biosimilar CT-P13 did not change the quality of life and clinical efficacy for IBD patients in stable remission in daily clinical practice (interim analysis)
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.J. Pierik1, A.E. van der Meulen-de Jong2, J.P.J. Bloemsaat-Minekus3*, Y.J.B. van Megen3, G. Dijkstra4

Created: Thursday, 21 February 2019, 9:14 AM
P465 Therapeutic drug monitoring in Crohn’s disease patients, a comparison between homogeneous mobility shift assay and point of care method
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Bodini1, M.G. Demarzo1, A. Djahandideh1, I. Baldissarro1, E. Savarino2, V. Savarino3, A. Jain4, P.M. Risso3, E.G. Giannini3

Created: Thursday, 30 January 2020, 10:12 AM
P465: Do infliximab trough levels differ between adult and paediatric patients with Crohn’s disease in clinical remission?
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Cavazza1*, N. Mavroeidi1, A. Steel2, L. Greathead1, W. Kelleher1, M. Wahed1

Created: Thursday, 21 February 2019, 9:14 AM
P465: Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Li K.*1, Chan D.1, Pollack P.1, Jacobstein D.1, Brodmerkel C.1, Gasink C.1, Feagan B.G.2, Sandborn W.3, Rutgeerts P.4, De Hertogh G.5

Created: Wednesday, 20 February 2019, 10:36 AM
P465: Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Armuzzi, A.(1)*;Rubin, D.T.(2);Schreiber, S.(3);Panés, J.(4);Fellmann, M.(5);Bartolome, L.(6);Goetsch, M.(7);Bhattacharjee, A.(8);Wu, J.(9);Chaparro, M.(10);Dubinsky, M.C.(11);
Created: Friday, 14 July 2023, 11:05 AM
P465: Indication-specific feasibility assessment of a placebo-controlled randomised mesalazine withdrawal study for paediatric patients with ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

N. Croft1, W. Faubion2, D. Tierens3, J. Dewulf3, D. Bwirire3, D. Stefani-Hunyady4, F. Cataldi*5

Created: Friday, 22 February 2019, 9:49 AM
P465: Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?
Year: 2022
Source: ECCO'22
Authors: Fumery, M.(1);Nancey, S.(2);Filippi, J.(3);Altwegg, R.(4);Hebuterne, X.(3);Boschetti, G.(2);Veyrard , P.(5);Yzet, C.(1);Paul, S.(6);Roblin, X.(5);
Created: Friday, 11 February 2022, 3:52 PM
P465: One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Verstockt., B.(1,2);Aden, K.(3,4);Alsoud, D.(2);Outtier, A.(1);Sabino, J.(1,2);Rosenstiel, P.(3,4);Vermeire, S.(1,2);De Hertogh, G.(5);Schreiber, S.(3,4);Ferrante, M.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P465: UC trial designed more than 5 years ago in the light of the EMA guideline on the development of new medicinal products for the treatment of ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Laoun*1, R. Hofmann2

Created: Friday, 22 February 2019, 9:41 AM
P466 Is it possible avoid colectomy with rescue dual therapy with vedolizumab plus tacrolimus in ulcerative colitis that losing response to anti-tumour necrosis factor?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Sanchis1, J.R. Molés1, J. Borrás2, J. Rodriguez1, X. Cortés1

Created: Thursday, 30 January 2020, 10:12 AM
P466: Acetarsol is an effective and safe option in the management of refractory ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Argyriou1*, R.J.M. Ingram1, R. Blatt2, P. Wilson2, S. Samuel1, C. Hawkey1, G.W. Moran1,3

Created: Thursday, 21 February 2019, 9:14 AM
P466: Acute Severe Ulcerative Colitis in the modern era: biologic therapy-exposed patients and salvage therapy with intensified infliximab.
Year: 2021
Source: ECCO'21 Virtual
Authors: Fasoulas, K.(1);Soufleris, K.(1);Kafalis, N.(1);Kevrekidou, P.(1);Bouzoukas, S.(1);Stergiou, E.(1);Dimitriadis, N.(1);Chatzopoulos, E.(1);Tzilves, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P466: Efficacy and safety outcomes in patients with moderate to severe ulcerative colitis stratified by ethnicity and race: a pooled analysis of data from GEMINI 1, VARSITY, and VISIBLE 1
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mukherjee , R.(1);Khan , R.M.Q.(1);Liu , J.J.(2);Ananthakrishnan , A.N.(3);Lichtenstein , G.R.(4)*;Uddin , S.(1);Young , L.(1);Boules , M.(1);Adamson , P.(2);Reeves , V.(5);
Created: Friday, 14 July 2023, 11:05 AM
P466: Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Schreiber S.1, Dignass A.*2, Peyrin-Biroulet L.3, Hather G.4, Demuth D.5, Khalid J.M.6, Loftus E.V.7

Created: Wednesday, 20 February 2019, 10:36 AM